drugset / Trial / NCT00697762

Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

NCT00697762

Phase 3 Terminated 56 enrolled SK Life Science, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the effectiveness and safety of adjunctive RWJ-333369 at a dose of 200 or 400 mg/day in comparison with placebo in Korean and Japanese partial epilepsy patients who have poor seizure control with one or two antiepileptics (AEDs).

Timeline

Start
2007-10
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Carisbamate Small molecule 100 mg Oral
Subject Carisbamate Small molecule 200 mg Oral

Indications